Physician profile
Laura C Wolfe
NPI 1053468942
$5,801.57
in general payments reported to CMS, 2019-2025
31 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $883 · 2021: $1,345 · 2022: $1,303 · 2023: $684 · 2024: $670 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,485.90 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $612.91 | 2019-2024 | Trulance, Xifaxan, Relistor |
| Celgene Corporation | $521.28 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $247.25 | 2019-2022 | |
| Braintree Laboratories, INC. | $237.64 | 2019-2024 | Sutab, Suflave |
| Qol Medical, LLC | $237.36 | 2020-2024 | Sucraid |
| Pfizer INC. | $204.60 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.81 | 2019-2022 | |
| Gilead Sciences, INC. | $137.04 | 2020-2024 | |
| Ironwood Pharmaceuticals, INC | $120.34 | 2020-2023 | Linzess |
| Genzyme Corporation | $115.91 | 2022-2025 | |
| Alfasigma USA, INC. | $105.51 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $81.01 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $46.05 | 2021-2022 | |
| Echosens North America, INC. | $45.45 | 2022-2024 | Fibroscan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $44.56 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $44.55 | 2025 | Rezdiffra |
| Organon LLC | $34.89 | 2022 | |
| Ethicon US, LLC | $33.27 | 2019 | |
| Laborie Medical Technologies Corp. | $33.11 | 2024 | |
| Amgen INC. | $31.97 | 2020 | |
| Ferring Pharmaceuticals INC. | $28.17 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $28.09 | 2019-2020 | |
| Shire North American Group INC | $24.31 | 2019 | |
| Redhill Biopharma INC. | $22.47 | 2022 | |
| Fresenius Kabi USA, LLC | $22.17 | 2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $21.69 | 2022 | |
| Sanofi US Services INC. | $20.97 | 2025 | |
| Merck Sharp & Dohme LLC | $19.49 | 2023 | Dificid |
| Ucb, INC. | $15.06 | 2019 | |
| Allergan, INC. | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.